Sunesis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNSS)


Share on StockTwits

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of some unusual options trading on Tuesday. Investors acquired 3,905 call options on the stock. This represents an increase of approximately 961% compared to the average daily volume of 368 call options.

SNSS stock traded up $0.78 during trading on Tuesday, hitting $4.34. The stock had a trading volume of 556,775 shares, compared to its average volume of 1,143,574. Sunesis Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $11.30. The stock has a market capitalization of $78.52 million, a P/E ratio of -2.15 and a beta of 2.27. The company’s 50-day moving average price is $2.95 and its two-hundred day moving average price is $2.04.

Separately, Oppenheimer upgraded Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

A number of hedge funds have recently bought and sold shares of SNSS. GSA Capital Partners LLP acquired a new stake in Sunesis Pharmaceuticals in the 3rd quarter worth about $41,000. Sowell Financial Services LLC acquired a new stake in Sunesis Pharmaceuticals in the 4th quarter worth about $30,000. 20 20 Capital Management Inc. acquired a new stake in Sunesis Pharmaceuticals in the 4th quarter worth about $29,000. Monashee Investment Management LLC acquired a new stake in Sunesis Pharmaceuticals in the 4th quarter worth about $693,000. Finally, Ikarian Capital LLC acquired a new stake in Sunesis Pharmaceuticals in the 4th quarter worth about $398,000. Institutional investors own 28.41% of the company’s stock.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies.

Read More: What are the benefits of investing in REITs?

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.